# Zoetis: quality near the top of our coverage, sitting in the sweet spot near its 52-week low

Zoetis (ZTS), In the Sweet Spot pick for July 9, 2026: Zoetis combines a 95.1 quality percentile with an 18.5% projected return, landing in our sweet spot wh...

Canonical: https://www.manifestinvesting.com/sweet-spot/zts-zoetis-2026-07-09

In the Sweet Spot · July 9, 2026 · Zoetis (ZTS) · Healthcare

**Zoetis combines a 95.1 quality percentile with an 18.5% projected return, landing in our sweet spot while trading just above its 52-week low ahead of an August 6 earnings report.**

Zoetis (ZTS) was Manifest Investing's In the Sweet Spot daily stock pick for July 9, 2026. At the time of the pick, Zoetis carried a quality percentile of 95 and a projected annual return (PAR) of 18.5% against a MIPAR of 8.8%, placing it inside the sweet spot of 13.8% to 18.8%.

## Key metrics at the time of the pick

- **Quality percentile**: 95
- **Projected annual return (PAR)**: 18.5%
- **MIPAR (median PAR of coverage)**: 8.8%
- **PROVE**: 12.8%
- **Core score (of 300)**: 284
- **Financial strength (of 100)**: 91
- **EPS stability (of 100)**: 97.7
- **Sales growth forecast**: 5.3%
- **P/E ratio**: 17.5
- **Price at pick**: $75.10
- **52-week low**: $71.47
- **52-week high**: $161.77
- **Above 52-week low**: 5.1%
- **Below 52-week high**: 53.6%
- **Dividend yield**: 2.6%
- **Projected yield**: 1.7%
- **In the sweet spot**: Yes
- **Triple play**: No

## Why Zoetis stands out today

Zoetis (ZTS), the animal-health company spun out of Pfizer, screens today as one of the more interesting combinations of quality and projected return in our coverage. At a quality percentile of 95.1 (ranking ahead of roughly 95% of the companies we follow), Zoetis carries a Projected Annual Return (PAR) of 18.5%. PAR is our forward-looking estimate of annualized total return over roughly the next five years, built from a sales growth forecast, projected margins, and the P/E the market is likely to assign at the end of that stretch. With MIPAR (the median PAR across everything we follow) at 8.8%, the sweet spot we look for runs from 13.8% to 18.8% (MIPAR + 5 to +10 points). Zoetis’s 18.5% PAR puts it right near the top of that band, comfortably inside it.

A few supporting data points:

- **Financial strength**: 91 out of 100, a solid balance sheet reading.
- **EPS stability**: 97.7 out of 100, among the smoothest earnings track records we track.
- **Core Score**: 284 out of 300 (quality percentile + financial strength + EPS stability, each on their own 0-100 scale). Anything above 225 is the threshold we associate with “core holding” candidates, so 284 is well past it.
- **Price positioning**: shares sit at $75.10, just 5.1% above the 52-week low of $71.47 and 53.6% below the 52-week high of $161.77. That’s a meaningful pullback from the annual high, and it’s part of why the projected return looks as attractive as it does. PAR moves inversely to price: when the price falls and the fundamentals hold, the projected return rises.
- **Growth and yield**: the growth forecast embedded in the model is 5.3%, current dividend yield is 2.65%, with a projected yield of 1.7%. The current P/E is 17.5.

**Why today specifically**: Zoetis reports next-quarter earnings on August 6, 2026, giving investors a concrete near-term checkpoint. On the operating side, Zoetis also picked up European Commission approval this week for a new poultry vaccine, one small data point on the pipeline side of the business.

For context, the Wall Street consensus price target across covering analysts is $110.57, per our data aggregator. We mention that as an outside reference point only, not as a blend with our own PAR methodology, which are two different lenses on the stock.

As always, this is a research lens, not a recommendation. The combination of high quality, a sweet-spot PAR, and proximity to a 52-week low is the kind of setup worth studying more closely, not a signal to act on by itself.

## Sources

- [ZTS Wins European Commission Approval for New Poultry Disease Vaccine](https://www.zacks.com/stock/news/2950221/zts-wins-european-commission-approval-for-new-poultry-disease-vaccine?cid=CS-STOCKNEWSAPI-FT-analyst_blog|company_news_medical_sector-2950221)

Zoetis has also been the In the Sweet Spot pick on: [August 14, 2026](/sweet-spot/zts-zoetis-2026-08-14).

## About In the Sweet Spot

Manifest Investing's daily stock pick: one high-quality company whose projected annual return (PAR) sits in the sweet spot above the market median (MIPAR). Each pick pairs Manifest Investing's quality percentile with its projected annual return (PAR); the sweet spot runs from MIPAR + 5 to MIPAR + 10 percentage points. Browse [every pick in the archive](/sweet-spot/archive).

_In the Sweet Spot is educational and is not investment advice or a recommendation to buy or sell any security. Figures reflect Manifest Investing's methodology as of the pick date._